K20
K20 is a potent and selective KRas G12C inhibitor with an IC50 of 1.16 µM. K20 shows anticancer activity in H358 cells (IC50= 0.78 µM). K20 decreases the levels of phosphorylated Erk and leads to cancer cell apoptosis. K20 suppresses NCI-H358 tumor growth with a TGI of 41% without causing obvious toxicity.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Formule: C24H20Cl2F4N4O2
- Masse moléculaire:543.34
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Activité biologique
|
KRAS(G12C) 1.16 μM (IC50) |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| NCI-H23 | IC50 |
1.55 μM
Compound: 13
|
Antiproliferative activity against human NCI-H23 cells harboring KRAS G12C mutant assessed as inhibition of cell growth
Antiproliferative activity against human NCI-H23 cells harboring KRAS G12C mutant assessed as inhibition of cell growth
|
[PMID: 36680986] |
| NCI-H358 | IC50 |
0.78 μM
Compound: 13
|
Antiproliferative activity against human NCI-H358 cells harboring KRAS G12C mutant assessed as inhibition of cell growth
Antiproliferative activity against human NCI-H358 cells harboring KRAS G12C mutant assessed as inhibition of cell growth
|
[PMID: 36680986] |
K20 (24 h) shows selective cytotoxicity (5 to 23-fold) against KRas G12C mutated cells (H358, IC50=0.78 µM) over other KRas mutant (e.g.G12D, G12D, G12S, G12V) cancer cells (IC50s of 6.34, 17.74, 4.78, 5.03, 4.05 µM in HCT116 (G13D), A549 (G12S), Pancl (G12D), Hela (WT), SW620 (G12V), respectively)[1].
K20 (0, 0.5, 2 µM; 24 h) induces apoptosis of NCI-H358 cells[1].
K20 (0, 0.5, 1.0, 2.5, 5.0 µM; 48 h) decreases pErk (phosphorylated Erk) levels in NCI-H358 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:H358, H23, HCT116, A549, Pancl, Hela, SW620 cells
-
Concentration:
-
Incubation Time:24 h
-
Result:Showed selective cytotoxicity (5 to 23-fold) against KRas G12C mutated cells (H358, IC50=0.78 µM) over other KRas mutant (e.g.G12D, G12D, G12S, G12V) cancer cells (IC50s of 6.34, 17.74, 4.78, 5.03, 4.05 µM in HCT116 (G13D), A549 (G12S), Pancl (G12D), Hela (WT), SW620 (G12V), respectively).
-
Cell Line:NCI-H358 cells
-
Concentration:0, 0.5, 2 µM
-
Incubation Time:24 h
-
Result:Induced apoptosis of NCI-H358 cells.
-
Cell Line:NCI-H358 cells
-
Concentration:0, 0.5, 1.0, 2.5, 5.0 µM
-
Incubation Time:48 h
-
Result:Decreased pErk (phosphorylated Erk) levels in NCI-H358 cells.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:6-week-old male BALB/c nude mice ( xenograft model)[1]
-
Dosage:35 mg/kg (dissolved in a 5%:35%:60% ratio of DMSO: castor oil: normal saline solution)
-
Administration:i.p.; every other day; 14 days
-
Result:Showed high tumor suppressive effects with a tumor growth inhibition (TGI) of 41% at 35 mg/kg.
Chemical Information
-
Masse moléculaire 543.34
-
Formule C24H20Cl2F4N4O2
-
SMILES
C=C(C(N1CCN([C@@H](C1)C)C2=NC=NC3=C(C(C4=CC(Cl)=CC=C4OC)=C(C=C23)Cl)F)=O)C(F)(F)F
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)